• A Corrigendum to this article was published on 18 July 2012

This article has been updated


We devised a high-throughput chemoproteomics method that enabled multiplexed screening of 16,000 compounds against native protein and lipid kinases in cell extracts. Optimization of one chemical series resulted in CZC24832, which is to our knowledge the first selective inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with efficacy in in vitro and in vivo models of inflammation. Extensive target- and cell-based profiling of CZC24832 revealed regulation of interleukin-17–producing T helper cell (TH17) differentiation by PI3Kγ, thus reinforcing selective inhibition of PI3Kγ as a potential treatment for inflammatory and autoimmune diseases.

  • Compound C19H16N6O3S


  • Compound C19H16N6O3S


  • Compound C17H20N6O3S


  • Compound C17H20N6O3S


  • Compound C20H15F3N6O4S


  • Compound C20H15F3N6O4S


  • Compound C19H15ClN6O3S


  • Compound C19H15ClN6O3S


  • Compound C18H13F3N6O2S


  • Compound C18H13F3N6O2S


  • Compound C18H13F3N6O2S


  • Compound C18H13F3N6O2S


  • Compound C18H13F3N6O2S


  • Compound C18H13F3N6O2S


  • Compound C20H20N6O2S


  • Compound C20H20N6O2S


  • Compound C17H13ClN6O2S


  • Compound C17H13ClN6O2S


  • Compound C19H12F6N6O2S


  • Compound C19H12F6N6O2S


  • Compound C14H14N4O2


  • Compound C14H13FN4O2


  • Compound C15H18N6O2S


  • Compound C15H17FN6O2S


  • Compound C12H12N6O2S


  • Compound C12H11FN6O2S


  • Compound C14H16N6O2S


  • Compound C14H15FN6O2S


  • Compound C14H16N6O2S


  • Compound C14H15FN6O2S


  • Compound C14H14N6O2S


  • Compound C14H13FN6O2S


  • Compound C13H11F3N6O2S


  • Compound C13H10F4N6O2S


  • Compound C14H16N6O2S


  • Compound C14H15FN6O2S


  • Compound C12H8F3N5


  • Compound C12H7F4N5


  • Compound C13H14N6O2S


  • Compound C13H13FN6O2S


  • Compound C16H16N4O3


  • Compound C16H15FN4O3


  • Compound C13H11N5O


  • Compound C13H10FN5O


  • Compound C14H13N5O3S


  • Compound C14H12FN5O3S


  • Compound C23H27N9O4S


  • Compound C23H26FN9O4S


  • Compound C20H26N8O4S


  • Compound C20H25FN8O4S


  • Compound C22H28N8O4S


  • Compound C22H27FN8O4S


  • Compound C22H28N8O5S


  • Compound C22H27FN8O5S


  • Compound C23H29N11O3S


  • Compound C23H28FN11O3S


  • Compound C20H24N10O3S


  • Compound C20H23FN10O3S


  • Compound C20H23N9O4S


  • Compound C20H22FN9O4S


  • Compound C21H27N7O5S

    3-(Dimethylamino)-3-oxopropyl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C21H26FN7O5S

    3-(Dimethylamino)-3-oxopropyl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-8-fluoro-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C22H29N7O5S

    2-Morpholinoethyl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C22H28FN7O5S

    2-Morpholinoethyl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-8-fluoro-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C19H22N10O4S

    2-(2H-Tetrazol-5-yl)ethyl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C19H21FN10O4S

    2-(2H-Tetrazol-5-yl)ethyl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-8-fluoro-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C23H32N8O4S

    2-(4-Methylpiperazin-1-yl)ethyl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C23H31FN8O4S

    2-(4-Methylpiperazin-1-yl)ethyl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-8-fluoro-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C22H29N7O4S

    1-Methylpiperidin-4-yl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C22H28FN7O4S

    1-Methylpiperidin-4-yl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-8-fluoro-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C17H20N6O4S

    Methyl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C17H19FN6O4S

    Methyl 6-(5-(N-tert-butylsulfamoyl)pyridin-3-yl)-8-fluoro-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C12H11N5O2S


  • Compound C17H19N7O4S


  • Compound C20H20N8O4S


  • Compound C19H22N6O4


  • Compound C16H16N4O4

    Methyl 6-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylcarbamate

  • Compound C19H24N8O4S


  • Compound C22H32ClN3O7S2


  • Compound C20H20N2O3


  • Compound C27H26N8O3


  • Compound C19H17NO3


  • Compound C12H7N3O2S


  • Compound C14H16ClN3O4S2


  • Compound C19H16N4O3


  • Compound C30H23N5O


  • Compound C14H8FNO4S


  • Compound C21H24N4O2


  • Compound C22H19N7O


  • Compound C23H27N7O3S2


Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 16 May 2012

    In the version of this article initially published, the name M. Sunose was misspelled in the Acknowledgements. The error has been corrected in the HTML and PDF versions of the article.


Protein Data Bank


  1. 1.

    , , & The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329–341 (2010).

  2. 2.

    , , & Signalling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34, 647–662 (2006).

  3. 3.

    et al. PI3Kγ adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P3 pools in mast cells. Sci. Signal. 2, ra27 (2009).

  4. 4.

    , , & PI3K inhibition in inflammation: toward tailored therapies for specific diseases. Bioessays 32, 185–196 (2010).

  5. 5.

    et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366–370 (2006).

  6. 6.

    et al. Inactivation of PI3Kγ and PI3Kδ distorts T-cell development and causes multiple organ inflammation. Blood 110, 2940–2947 (2007).

  7. 7.

    et al. Phosphoinositide 3-kinase p110β activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal. 1, ra3 (2008).

  8. 8.

    et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851–1863 (2008).

  9. 9.

    et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. USA 106, 22299–22304 (2009).

  10. 10.

    et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 69, 7644–7652 (2009).

  11. 11.

    et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 18, 721–727 (2011).

  12. 12.

    et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007).

  13. 13.

    et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255–265 (2011).

  14. 14.

    et al. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 25, 89–100 (2011).

  15. 15.

    et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733–747 (2006).

  16. 16.

    , , & A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H–1-benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241–5248 (1994).

  17. 17.

    , & Selectivity profiling of PI3K interacting molecules against multiple targets. European patent EP2245181 (2011).

  18. 18.

    et al. A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Rep. 9, 164–170 (2008).

  19. 19.

    et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741–744 (2009).

  20. 20.

    et al. Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J. Pharmacol. Toxicol. Methods 61, 3–15 (2010).

  21. 21.

    et al. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 287, 1049–1053 (2000).

  22. 22.

    et al. Requirement for PI 3-kinase γ in macrophage migration to MCP-1 and CSF-1. Exp. Cell Res. 290, 120–131 (2003).

  23. 23.

    et al. Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays. J. Am. Soc. Mass Spectrom. 21, 1668–1679 (2010).

  24. 24.

    et al. Discovery of dual inhibitors of the immune cell PI3Ks p110δ and p110γ: a prototype for new anti-inflammatory drugs. Chem. Biol. 17, 123–134 (2010).

  25. 25.

    et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc. Natl. Acad. Sci. USA 107, 14292–14297 (2010).

  26. 26.

    et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8, 967–974 (2007).

  27. 27.

    et al. PI3Kγ modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375–387 (2004).

  28. 28.

    , & PI3K δ and PI3K γ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7, 191–201 (2007).

  29. 29.

    , & PI3Kγ inhibition: towards an 'aspirin of the 21st century'? Nat. Rev. Drug Discov. 5, 903–918 (2006).

  30. 30.

    et al. PI3Kγ mediates Kaposi's sarcoma–associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell 19, 805–813 (2011).

  31. 31.

    et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19, 715–727 (2011).

  32. 32.

    et al. PI3Kγ within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 108, E854–E863 (2011).

  33. 33.

    et al. Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance. Proc. Natl. Acad. Sci. USA 108, 5753–5758 (2011).

  34. 34.

    et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-γ reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 117, 1310–1317 (2008).

  35. 35.

    et al. Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem. Biol. 17, 686–694 (2010).

  36. 36.

    et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62, 1364–1372 (2002).

  37. 37.

    et al. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936–943 (2005).

  38. 38.

    et al. Key role of the p110δ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110δ function in B cells. Blood 107, 642–650 (2006).

  39. 39.

    et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106, 1432–1440 (2005).

  40. 40.

    et al. Protection from angiotensin II–mediated vasculotoxic and hypertensive response in mice lacking PI3Kγ. J. Exp. Med. 201, 1217–1228 (2005).

  41. 41.

    et al. PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting TH17 differentiation. J. Autoimmun. 36, 278–287 (2011).

  42. 42.

    et al. Phosphoinositide 3-kinases γ and δ, linkers of coordinate C5a receptor-Fcγ receptor activation and immune complex-induced inflammation. J. Biol. Chem. 283, 33296–33303 (2008).

  43. 43.

    et al. Treatment with a neutralizing anti–murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50, 650–659 (2004).

  44. 44.

    et al. LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62, 929–939 (2010).

  45. 45.

    , & Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod. Rheumatol. 19, 657–662 (2009).

  46. 46.

    et al. Delayed fragmentation and optimized isolation width settings for improvement of protein identification and accuracy of isobaric mass tag quantification on Orbitrap-type mass spectrometers. Anal. Chem. 83, 8959–8967 (2011).

  47. 47.

    , , , & Evaluation of data analysis strategies for improved mass spectrometry-based phosphoproteomics. Anal. Chem. 82, 9843–9849 (2010).

  48. 48.

    et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J. 18, 1279–1281 (2004).

  49. 49.

    et al. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev. Technol. 2, 431–441 (2004).

Download references


We are grateful to M. Sunhose and W. Miller for chemistry and cheminformatics support; MS, information technology, biochemistry and biology groups for technical support; G. Creighton-Gutteridge for experimental support; F. Weisbrodt for assistance with graphics; G. Bennett (Cellzome Ltd.) and O. Azzolino (University of Torino) for animal data; Y. Abraham for generation of the cladogram; R. Hale and T. Edwards for general advice; and M. Wymann, D. Simmons and A. Watt for stimulating discussions and valuable comments.

Author information


  1. Cellzome AG, Heidelberg, Germany.

    • Giovanna Bergamini
    • , Satoko Shimamura
    • , Thilo Werner
    • , Katrin Müller
    • , Jessica Perrin
    • , Christina Rau
    • , Carsten Hopf
    • , Carola Doce
    • , Toby Mathieson
    • , Faiza Rharbaoui
    • , Friedrich Reinhard
    • , Mikhail M Savitski
    • , Gerard Drewes
    • , Marcus Bantscheff
    •  & Gitte Neubauer
  2. Cellzome Ltd., Chesterford Research Park, Cambridge, UK.

    • Kathryn Bell
    • , Andrew Cansfield
    • , Katie Ellard
    • , Daniel Leggate
    • , Raffaella Mangano
    • , Nigel Ramsden
    •  & Oliver Rausch
  3. BioSeek LLC, San Francisco, California, USA.

    • Alison O'Mahony
    •  & Ivan Plavec
  4. Department of Genetics, Biology and Biochemistry, Molecular Biotechnology Center, University of Torino, Torino, Italy.

    • Emilio Hirsch


  1. Search for Giovanna Bergamini in:

  2. Search for Kathryn Bell in:

  3. Search for Satoko Shimamura in:

  4. Search for Thilo Werner in:

  5. Search for Andrew Cansfield in:

  6. Search for Katrin Müller in:

  7. Search for Jessica Perrin in:

  8. Search for Christina Rau in:

  9. Search for Katie Ellard in:

  10. Search for Carsten Hopf in:

  11. Search for Carola Doce in:

  12. Search for Daniel Leggate in:

  13. Search for Raffaella Mangano in:

  14. Search for Toby Mathieson in:

  15. Search for Alison O'Mahony in:

  16. Search for Ivan Plavec in:

  17. Search for Faiza Rharbaoui in:

  18. Search for Friedrich Reinhard in:

  19. Search for Mikhail M Savitski in:

  20. Search for Nigel Ramsden in:

  21. Search for Emilio Hirsch in:

  22. Search for Gerard Drewes in:

  23. Search for Oliver Rausch in:

  24. Search for Marcus Bantscheff in:

  25. Search for Gitte Neubauer in:


G.B., S.S., K.M. and J.P. developed and performed assays; K.B., A.C. and K.E. designed and synthesized compounds; C.R., F. Reinhard, D.L. and R.M. performed screening; F. Rharbaoui contributed to animal studies; M.M.S., T.M. and M.B. developed MS technology; C.D. supported data analysis and display; A.O. and I.P. contributed cellular activity profiles; T.W. designed and performed MS experiments; C.H. supervised biochemistry work; G.D. contributed to the manuscript and gave advice; E.H. gave general advice and contributed animal data; N.R. led the chemistry efforts; O.R. contributed to data analysis and manuscript preparation; and G.B., M.B. and G.N. designed and supervised the study, analyzed data and wrote the manuscript.

Competing interests

G.B., S.S., T.W., K.M., J.P., C.R., A.H., C.D., T.M., F. Rharbaoui, F. Reinhard, M.M.S., G.D., M.B. and G.N. are employees of Cellzome AG; K.B., A.C., K.E., D.L., R.M., N.R. and O.R. are employees of Cellzome Ltd.; and A.M. and I.P. are employees of BioSeek Inc.

Corresponding authors

Correspondence to Marcus Bantscheff or Gitte Neubauer.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Methods and Supplementary Results

Excel files

  1. 1.

    Supplementary Data Set 1

    Complementary kinase capturing of CZC15098 and CZC15292 derived bead matrices in different cell extracts

  2. 2.

    Supplementary Data Set 2

    Concentration-inhibition profiles for all reference compounds and CZC19945 and CZC24832 in different cell extracts

  3. 3.

    Supplementary Data Set 3

    Correction factors for calculation of apparent dissociation constants from IC50s obtained in profiling experiments using kinobeads and HL60 cell extracts

  4. 4.

    Supplementary Data Set 4

    Correction factors for calculation of apparent dissociation constants from IC50s obtained in profiling experiments using LK beads and HL60 cell extracts

  5. 5.

    Supplementary Data Set 5

    Proteomic binding profiles using an immobilized linkable analogue of CZC19945/CZC24832 as probe matrix and HeLa, HL60, and PBMC cell extracts

  6. 6.

    Supplementary Data Set 6

    Correction factors for calculation of apparent dissociation constants from IC50s obtained in profiling experiments using LK beads and mixed raw264.7, HL60 cell extracts

  7. 7.

    Supplementary Data Set 7

    Correction factors for calculation of apparent dissociation constants from IC50s obtained in profiling experiments using LK beads and mixed RBL-1, HL60 cell extracts

About this article

Publication history






Further reading